Obermeyer Wood Investment Counsel Lllp Decreases Stock Holdings in Pfizer Inc. (NYSE:PFE)

Obermeyer Wood Investment Counsel Lllp decreased its stake in shares of Pfizer Inc. (NYSE:PFE) by 10.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 35,748 shares of the biopharmaceutical company’s stock after selling 3,984 shares during the period. Obermeyer Wood Investment Counsel Lllp’s holdings in Pfizer were worth $1,029,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Xponance Inc. raised its holdings in shares of Pfizer by 11.5% during the fourth quarter. Xponance Inc. now owns 891,024 shares of the biopharmaceutical company’s stock valued at $25,653,000 after purchasing an additional 91,843 shares during the last quarter. Integral Investment Advisors Inc. boosted its position in shares of Pfizer by 15.7% in the fourth quarter. Integral Investment Advisors Inc. now owns 19,513 shares of the biopharmaceutical company’s stock worth $562,000 after purchasing an additional 2,649 shares during the period. Investors Asset Management of Georgia Inc. GA ADV boosted its position in shares of Pfizer by 1.9% during the fourth quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 64,890 shares of the biopharmaceutical company’s stock worth $1,884,000 after acquiring an additional 1,217 shares during the last quarter. Wright Investors Service Inc. boosted its position in shares of Pfizer by 6.5% during the fourth quarter. Wright Investors Service Inc. now owns 50,949 shares of the biopharmaceutical company’s stock worth $1,467,000 after acquiring an additional 3,127 shares during the last quarter. Finally, HF Advisory Group LLC boosted its position in shares of Pfizer by 20.5% during the fourth quarter. HF Advisory Group LLC now owns 67,611 shares of the biopharmaceutical company’s stock worth $1,947,000 after acquiring an additional 11,479 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

PFE stock traded up $0.16 during trading on Friday, reaching $25.55. The company had a trading volume of 7,637,767 shares, compared to its average volume of 41,995,176. The firm has a 50-day simple moving average of $27.14 and a 200-day simple moving average of $28.74. The company has a market cap of $144.68 billion, a price-to-earnings ratio of 70.51, a price-to-earnings-growth ratio of 1.15 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. Pfizer Inc. has a twelve month low of $25.23 and a twelve month high of $40.37.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period last year, the firm posted $1.14 EPS. Pfizer’s revenue for the quarter was down 41.3% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.24 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on PFE. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Monday. TD Cowen downgraded shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a research note on Thursday, January 4th. Guggenheim initiated coverage on shares of Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.